Skip to Content

Hetastarch Pregnancy and Breastfeeding Warnings

Hetastarch is also known as: Hespan, Hextend

Medically reviewed on Jul 30, 2018

Hetastarch Pregnancy Warnings

FDA pregnancy category: C

Use only if the benefit outweighs the risk to the developing fetus.

Animal studies demonstrated embryocidal effects when given intravenously over the entire organogenesis period in a daily dose ½ times the maximum recommended therapeutic human dose, and when given intraperitoneally, from the 16 th to the 21 st day of pregnancy in a daily dose 2.3 times the maximum recommended therapeutic human dose.

There are no controlled data in human pregnancy.

FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Hetastarch Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Hespan (hetastarch)." B. Braun Medical, Irvine, CA.
  2. "Product Information. Hextend (hetastarch)." Abbott Pharmaceutical, Abbott Park, IL.

References for breastfeeding information

  1. "Product Information. Hespan (hetastarch)." B. Braun Medical, Irvine, CA.
  2. "Product Information. Hextend (hetastarch)." Abbott Pharmaceutical, Abbott Park, IL.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide